New research reveals that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Research printed in a leading health publication demonstrates that while obese people often shed about a fifth of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying such drugs need to be aware of the potential of fast weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight within about a year and a half.
Weighing Therapies
The analysis, which looked at dozens of trials involving over 9,000 of patients, contrasted the results of the injectable medications with other pills.
Researchers emphasize that individuals who shed pounds through diet and exercise generally experience a more gradual weight regain—approximately 100 grams monthly—once they finish.
The Reason for the Fast Regain
Experts propose the mode of action of the drugs is key to understanding the accelerated regain.
These medications copy a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of GLP-1 levels far above than normal could lead to the body to produce less of its endogenous GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement means appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Condition?
Medical guidelines suggest the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, considering the likelihood of relapse, the therapy should be considered long-term.
This opinion is supported by pharmaceutical companies, who note that the findings "underscore the long-term nature of obesity," comparing it to managing conditions like high blood pressure.
Patient Accounts
Individuals who have come off the jabs describe a intense resurgence of hunger.
"It felt as if something activating and I was suddenly ravenous," said one woman.
The struggle is compounded if users have not established sustainable dietary or behavioural modifications during treatment.
Significant Interest
Recent estimates indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is greater among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, researchers stress that while the jabs are powerful tools for shedding pounds, they are not a permanent fix and long-term success relies on ongoing behavioural management.
